- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Piramal Pharma reported ₹8,869 Cr revenue, ₹1,135 Cr EBITDA, and a ₹325.94 Cr net loss amid market headwinds. The company invested ₹890 Cr and US$90M in advanced therapies, boosting growth prospects. Operational excellence drove 22.6% emissions cut & 41% renewable energy, with advancing digital transformation.